Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 11.55am 04/10/2024 (20 minute delay)
?
Day | ||||||||
---|---|---|---|---|---|---|---|---|
Open | 1.0¢ | Day High | 1.1¢ | Day Low | 1.0¢ | |||
Daily Volume | 264895 |
Bids | Sellers | |||||
---|---|---|---|---|---|---|
Number | Price | Volume | Number | Price | Volume | |
7 | 1.0¢ | 1704825 | 8 | 1.2¢ | 1821450 |
Directors & Senior Management
Mr. Peng Zhang | Executive Chairman of the Board |
Mr. Adrian Costello | Chief Operating Officer, Executive Director |
Mr. Andrew Frazer | Executive Director |
Mr. Lloyd Flint | Company Secretary |
Mr. Xingmin JI | Non-Executive Director |
Data source: Refinitiv